Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report) shares traded up 11.6% during trading on Thursday . The company traded as high as $17.00 and last traded at $15.44. Approximately 409,503 shares were traded during trading, an increase of 717% from the average daily volume of 50,104 shares. The stock had previously closed at $13.83.
Neoleukin Therapeutics Price Performance
The firm has a market capitalization of $122.46 million, a PE ratio of -4.19 and a beta of 1.11. The stock's 50-day moving average price is $13.76 and its 200 day moving average price is $23.49.
Neoleukin Therapeutics Company Profile
(
Get Free Report)
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Read More
Before you consider Neoleukin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neoleukin Therapeutics wasn't on the list.
While Neoleukin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
